Effectiveness and safety of dolutegravir and raltegravir for treating children and adolescents living with HIV: a systematic review

Advancing the prevention and treatment of HIV in children: priorities for research and development

(2022) Martina Penazzato et al.   Lancet HIV

ODYSSEY clinical trial design: a randomised global study to evaluate the efficacy and safety of dolutegravir-based antiretroviral therapy in HIV-positive children, with nested pharmacokinetic sub-studies to evaluate pragmatic WHO-weight-band based dolutegravir dosing

(2021) Cecilia L. Moore et al.   BMC INFECTIOUS DISEASES

Dolutegravir as First- or Second-Line Treatment for HIV-1 Infection in Children

(2021) Anna Turkova et al.   NEW ENGLAND JOURNAL OF MEDICINE

Excess Weight Gain With Integrase Inhibitors and Tenofovir Alafenamide: What Is the Mechanism and Does It Matter?

(2021) Brian R Wood et al.   Open Forum Infectious Diseases

Raltegravir use and outcomes among children and adolescents living with HIV in the IeDEA global consortium

(2020) Gabriela Patten et al.   Journal of the International AIDS Society

Simplified dolutegravir dosing for children with HIV weighing 20 kg or more: pharmacokinetic and safety substudies of the multicentre, randomised ODYSSEY trial

(2020) Pauline D J Bollen et al.   Lancet HIV

Paediatric Integrase Inhibitor Use in a Real-Life Setting: A Single-Centre Cohort Experience 2009–2018

(2019) Yara-Natalie Abo et al.   CLINICAL DRUG INVESTIGATION

Similar efficacy and safety of dolutegravir between age groups of HIV ‐1‐infected paediatric and young adult patients aged 5 years and older

(2019) P Frange et al.   HIV MEDICINE

High rates of antiretroviral coverage and virological suppression in HIV-1-infected children and adolescents

(2019) A. Soumah et al.   MEDECINE ET MALADIES INFECTIEUSES

Weight gain and integrase inhibitors

(2019) Allison Ross Eckard et al.   CURRENT OPINION IN INFECTIOUS DISEASES

The transition to dolutegravir and other new antiretrovirals in low-income and middle-income countries

(2018) Marco Vitoria et al.   AIDS

Raltegravir-intensified initial antiretroviral therapy in advanced HIV disease in Africa: A randomised controlled trial

(2018) Cissy Kityo et al.   PLOS MEDICINE

Safety and efficacy at 240 weeks of different raltegravir formulations in children with HIV-1: a phase 1/2 open label, non-randomised, multicentre trial

(2018) Sharon Nachman et al.   Lancet HIV

Genotype-guided antiretroviral regimens in children with multidrug-resistant HIV-1 infection

(2016) Gloria Huerta-García et al.   PEDIATRIC RESEARCH

Safety, Pharmacokinetics and Efficacy of Dolutegravir in Treatment-experienced HIV-1 Infected Adolescents

(2015) Rolando M. Viani et al.   PEDIATRIC INFECTIOUS DISEASE JOURNAL

Pharmacokinetics and 48-Week Safety and Efficacy of Raltegravir for Oral Suspension in Human Immunodeficiency Virus Type-1-Infected Children 4 Weeks to 2 Years of Age

(2015) S. Nachman et al.   Journal of the Pediatric Infectious Diseases Society

Pharmacokinetics, Safety, and 48-Week Efficacy of Oral Raltegravir in HIV-1-Infected Children Aged 2 Through 18 Years

(2013) S. Nachman et al.   CLINICAL INFECTIOUS DISEASES

Clinical Pharmacokinetic, Pharmacodynamic and Drug-Interaction Profile of the Integrase Inhibitor Dolutegravir

(2013) Mackenzie L. Cottrell et al.   CLINICAL PHARMACOKINETICS

Potent and Sustained Antiviral Response of Raltegravir-based Highly Active Antiretroviral Therapy in HIV Type 1-infected Children and Adolescents

(2011) Verónica Briz et al.   PEDIATRIC INFECTIOUS DISEASE JOURNAL

Raltegravir, etravirine and r-darunavir combination in adolescents with multidrug-resistant virus

(2009) Isabelle Thuret et al.   AIDS